LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 1 | J24 | 72 | hr | 1476 | 2169 | 3694 | 0.5872 | 0.3122 |
| SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 2 | J24 | 72 | hr | 1476 | 2353 | 3694 | 0.6370 | 0.3952 |
| SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 3 | J24 | 72 | hr | 1476 | 2157 | 3694 | 0.5839 | 0.3068 |
| SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 1 | M12 | 72 | hr | 1476 | 2247 | 3694 | 0.6083 | 0.3474 |
| SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 2 | M12 | 72 | hr | 1476 | 2037 | 3694 | 0.5514 | 0.2527 |
| SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 3 | M12 | 72 | hr | 1476 | 1951 | 3694 | 0.5282 | 0.2139 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 1 | P18 | 72 | hr | 1476 | 3111 | 3694 | 0.8422 | 0.7371 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 2 | P18 | 72 | hr | 1476 | 3139 | 3694 | 0.8497 | 0.7497 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 3 | P18 | 72 | hr | 1476 | 2990 | 3694 | 0.8094 | 0.6825 |
| SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 1 | H06 | 72 | hr | 1476 | 3865 | 3694 | 1.0463 | 1.0771 |
| SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 2 | H06 | 72 | hr | 1476 | 3583 | 3694 | 0.9699 | 0.9499 |
| SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 3 | H06 | 72 | hr | 1476 | 3778 | 3694 | 1.0227 | 1.0379 |
| SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 1 | L24 | 72 | hr | 1476 | 3059 | 3694 | 0.8281 | 0.7136 |
| SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 2 | L24 | 72 | hr | 1476 | 2813 | 3694 | 0.7615 | 0.6027 |
| SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 3 | L24 | 72 | hr | 1476 | 2558 | 3694 | 0.6925 | 0.4877 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 1 | H12 | 72 | hr | 1476 | 1874 | 3694 | 0.5073 | 0.1792 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 2 | H12 | 72 | hr | 1476 | 1791 | 3694 | 0.4848 | 0.1417 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 3 | H12 | 72 | hr | 1476 | 1892 | 3694 | 0.5122 | 0.1873 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 1 | G12 | 72 | hr | 1476 | 3235 | 3694 | 0.8757 | 0.7930 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 2 | G12 | 72 | hr | 1476 | 3468 | 3694 | 0.9388 | 0.8981 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 3 | G12 | 72 | hr | 1476 | 3721 | 3694 | 1.0073 | 1.0122 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 1 | F06 | 72 | hr | 1476 | 3992 | 3694 | 1.0807 | 1.1344 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 2 | F06 | 72 | hr | 1476 | 4246 | 3694 | 1.1494 | 1.2489 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 3 | F06 | 72 | hr | 1476 | 4428 | 3694 | 1.1987 | 1.3310 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 1 | G06 | 72 | hr | 1476 | 834 | 3694 | 0.2258 | -0.2899 |